Study of ALXN1820 in Healthy Adult Participants

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This is a Phase 1, randomized, double-blind, placebo-controlled single and multiple ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of ALXN1820 administered subcutaneously (SC) (ALXN1820 SC) and intravenously (IV) (ALXN1820 IV).
Epistemonikos ID: 504c8b21ddeb6133d1e14caebfb181c460d64369
First added on: May 07, 2024